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Jeffrey J. Popma, MD,zz David J. Cohen, MD, MSC,y on behalf of the CoreValve U.S. Trial InvestigatorsABSTRACTOBJECTIVES The purpose of this study was to characterize health status outcomes after transcatheter aortic valve
replacement (TAVR) with a self-expanding bioprosthesis among patients at extreme surgical risk and to identify
pre-procedural patient characteristics associated with a poor outcome.
BACKGROUND For many patients considering TAVR, improvement in quality of life may be of even greater importance
than prolonged survival.
METHODS Patients with severe, symptomatic aortic stenosis who were considered to be at prohibitive risk for surgical
aortic valve replacement were enrolled in the single-arm CoreValve U.S. Extreme Risk Study. Health status was assessed
at baseline and at 1, 6, and 12 months after TAVR using the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Short
Form-12, and the EuroQol-5D. The overall summary scale of the KCCQ (range 0 to 100; higher scores ¼ better health)
was the primary health status outcome. A poor outcome after TAVR was deﬁned as death, a KCCQ overall summary score
(OS) <45, or a decline in KCCQ-OS of 10 points at 6-month follow-up.
RESULTS A total of 471 patients underwent TAVR via the transfemoral approach, of whom 436 (93%) completed
the baseline health status survey. All health status measures demonstrated considerable impairment at baseline.
After TAVR, there was substantial improvement in both disease-speciﬁc and generic health status measures,
with an increase in the KCCQ-OS of 23.9 points (95% conﬁdence interval [CI]: 20.3 to 27.5 points) at 1 month,
27.4 points (95% CI: 24.2 to 30.6 points) at 6 months, 27.4 points (95% CI: 24.1 to 30.8 points) at 12 months,
along with substantial increases in Short Form-12 scores and EuroQol-5D utilities (all p < 0.003 compared with
baseline). Nonetheless, 39% of patients had a poor outcome after TAVR. Baseline factors independently associ-
ated with poor outcome included wheelchair dependency, lower mean aortic valve gradient, prior coronary artery
bypass grafting, oxygen dependency, very high predicted mortality with surgical aortic valve replacement, and
low serum albumin.
CONCLUSIONS Among patients with severe aortic stenosis, TAVR with a self-expanding bioprosthesis resulted in
substantial improvements in both disease-speciﬁc and generic health-related quality of life, but there remained a large
minority of patients who died or had very poor quality of life despite TAVR. Predictive models based on a combination of
clinical factors as well as disability and frailty may provide insight into the optimal patient population for whom TAVR is
beneﬁcial. (Safety and Efﬁcacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe
Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement; NCT01240902) (J Am Coll
Cardiol Intv 2015;8:315–23) © 2015 by the American College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
EQ-5D = EuroQol-5D
KCCQ = Kansas City
Cardiomyopathy Questionnaire
SF-12 = Medical Outcomes
Study Short Form-12
TAVR = transcatheter aortic
valve replacement
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316A ortic stenosis is the most commonform of valvular heart disease inthe elderly and is associated with
high morbidity and mortality once cardiac
symptoms develop (1). In patients who are
at extreme risk for serious complications
during or after surgery, transcatheter aortic
valve replacement (TAVR) has been shown
to result in substantial reductions in mortal-
ity and improvement in quality of lifecompared with standard therapy (2,3). Despite these
health beneﬁts, patients at extreme risk who un-
dergo TAVR have high rates of both short- and
long-term mortality, with mortality rates of 30%
and 43% at 1 and 2 years, respectively (2,4). More-
over, given the advanced age and multiple comorbid
conditions that are invariably present in the extreme
risk population, improvements in quality of life may
be of even greater importance than improved
survival.
The CoreValve transcatheter heart valve (Med-
tronic, Inc., Minneapolis, Minnesota) is a self-
expanding bioprosthesis that is widely used outside
of the United States. In a recently completed trial,
the CoreValve heart valve was shown to be safe and
effective for patients with symptomatic severe aortic
stenosis at extreme risk for surgical valve replace-
ment (5), but the quality of life beneﬁts of this device
are unknown. To address this gap in knowledge, we
sought to characterize health status outcomes among
patients at extreme surgical risk who were enrolled
in the CoreValve U.S. Pivotal Trial. Our secondary
objective was to identify pre-procedural patient
characteristics (including comorbidities, surgical risk
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TAVR.
METHODS
STUDY DESIGN AND PATIENT POPULATION.
The design and results of the CoreValve U.S. Extreme
Risk Pivotal Trial have been reported previously (5).
Brieﬂy, the trial enrolled patients with severe aortic
stenosis and New York Heart Association functional
class II, III, or IV heart failure symptoms. Patients
were classiﬁed as extreme risk if the 30-day risk of
mortality or irreversible morbidity was estimated to
be $50% by 2 cardiac surgeons and 1 interventional
cardiologist (5). In the screening process, each patient
was reviewed in detail by a national screening com-
mittee that included at least 2 cardiac surgeons and 1
interventional cardiologist, each of whom had to
agree that the patient met eligibility, risk, and imag-
ing criteria for the trial. After conﬁrmation by the trial
oversight committee, patients underwent TAVR via
an iliofemoral approach, using the Medtronic self-
expanding CoreValve system (Medtronic, Inc.). The
study was approved by the institutional review board
at each site, and all patients provided written
informed consent prior to participation.
HEALTH STATUS ASSESSMENT. Disease-speciﬁc and
generic health status were assessed at baseline and
at 1, 6 and 12 months after enrollment using written
questionnaires. Questionnaires were administered
either during in-person visits to the study sites or
by mail. Disease-speciﬁc health status was assessed
with the Kansas City Cardiomyopathy Questionnaire
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317that assesses speciﬁc health domains pertaining to
heart failure: symptoms, physical limitation, social
limitation, self-efﬁcacy, and quality of life (6). The
individual domains can be combined into an overall
summary score (OS), which was the pre-speciﬁed
primary endpoint for this study. Values for all KCCQ
domains and the summary score range from 0 to 100,
with higher scores indicating less symptom burden
and better quality of life. Prior studies have shown
that the KCCQ-OS generally correlates with New York
Heart Association functional class as follows: class I:
KCCQ-OS 75 to 100; class II: 60 to 74; class III: 45 to 59;
and class IV: 0 to 44 (7,8). Changes in the KCCQ-OS of
5, 10, and 20 points correspond to small, moderate,
or large clinical improvements, respectively (7). The
KCCQ has been shown to be a reliable, responsive,
and valid measure of symptoms, functional status,
and quality of life among a variety of patients with
heart failure symptoms, including those with severe,
symptomatic aortic stenosis (8).
Generic health status was evaluated with the
Medical Outcomes Study Short Form-12 (SF-12) ques-
tionnaire (9) and the EuroQol-5D (EQ-5D) (10). Derived
from the Short Form-36, the SF-12 provides mental
and physical summary scores that are scaled to overall
U.S. norms of 50 with standard deviations of 10.
Higher scores indicate better quality of life, and the
minimum clinically-important difference for the SF-12
summary scores is 2 to 2.5 points (11). The EQ-5D is a
generic health status measure consisting of 5 domains
(mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), which can be converted to
utilities using an algorithm developed for the U.S.
population (12). Utilities are preference-weighted
health status assessments with scores that range
from 0 to 1, with 1 representing perfect health and
0 corresponding to the worst imaginable health
state (13).
STATISTICAL ANALYSIS. At each follow-up time-
point, scores for each of the disease-speciﬁc and
generic health status scores were compared with
baseline values using paired t tests. At each time-
point, the baseline value comparator consisted of
only those patients that had a quality-of-life assess-
ment performed at that time-point, thereby address-
ing survivor bias caused by attrition of sicker patients
over time.
To provide additional insight into the changes in
health status over time, we also performed several
categorical analyses. First, among the survivors at
each time-point, we calculated the proportion of pa-
tients who had a moderate ($10 points) or large ($20
points) improvement in the KCCQ-OS compared withbaseline. Second, we calculated the proportion of
enrolled patients at each time-point with favorable
and excellent outcomes, deﬁned as being both alive
and having a moderate or large improvement,
respectively, in the KCCQ-OS compared with base-
line. For these latter metrics, death was considered to
be the same as failure to improve by the speciﬁed
amount. The 95% conﬁdence interval for proportion
was based on the binomial distribution.
Finally, we calculated the proportion of patients
with a poor outcome at 6 months after TAVR. For this
analysis, a poor outcome was deﬁned as any of the
following at 6 months after TAVR: 1) death; 2) KCCQ-
OS <45 points; or 3) decrease of $10 points on the
KCCQ-OS from baseline (14). We then used multivar-
iable logistic regression to identify pre-procedural
factors associated with poor 6-month outcome.
Candidate variables for this analysis are listed in
Online Table 1. We used stepwise selection to identify
variables associated with poor outcome at a signiﬁ-
cance level of p # 0.10, and then reﬁt the model with
the identiﬁed variables. The baseline score on the
KCCQ-OS was forced into the model.
All statistical analyses were performed using SAS
software, version 9.2 (SAS Institute, Inc., Cary, North
Carolina). A 2-sided p value <0.05 was considered
statistically signiﬁcant with no correction for multiple
comparisons.
RESULTS
PATIENT POPULATION. Between February 2011 and
August 2012, 737 patients with severe symptomatic
aortic stenosis and at extreme surgical risk from 41
U.S. sites were approved by the trial screening com-
mittee for inclusion in the CoreValve U.S. Extreme
Risk Study. Of these, 18 were not enrolled (due to
withdrawal by the patient or treating physician), 85
were roll-in patients or were treated in a separate
registry with the 23-mm CoreValve, and 147 were
planned for noniliofemoral access, leaving 487 pa-
tients in the intention-to-treat population. Sixteen
patients subsequently did not undergo iliofemoral
TAVR, and an additional 35 did not have baseline
health status data. With the exception of being
somewhat younger, patients with missing baseline
health status assessments were generally similar to
those patients with complete baseline data (Online
Table 2). As such, the analytic population for our
study included 436 patients who underwent iliofe-
moral TAVR and had baseline health status assess-
ment (Figure 1).
The baseline characteristics of these patients are
summarized in Table 1. The mean age was 84 years,
FIGURE 1 Patient Flow Chart
Consort diagram showing patient ﬂow for the CoreValve U.S. Pivotal trial. The black
box indicates the primary analytic population for this quality of life (QOL) study.
ITT ¼ intention to treat.
TABLE 1 Baseline Characteristics of the CoreValve Extreme Risk
Cohort in the “As Treated” Population (n ¼ 436)
Sociodemographic characteristics
Age, yrs 84.0  8.5
Male 49.1 (214/436)
White race 95.6 (417/436)
Body mass index, kg/m2 28.6  7.0
Clinical characteristics
STS risk score 10.4  5.6
<5 12.6 (55/436)
5–<10 42.7 (186/436)
10–<15 26.1 (114/436)
$15 18.6 (81/436)
Logistic EuroSCORE 22.8  17.7
NYHA functional class
II 8.3 (36/434)
III 65.0 (282/434)
IV 26.7 (116/434)
Prior MI 31.7 (138/436)
Prior CABG 40.6 (177/436)
Prior stroke 13.8 (60/436)
Home oxygen 29.8 (130/436)
Chronic kidney disease 13.2 (57/431)
Mean aortic valve gradient, mm Hg 47.6  14.8
Frailty and disability measures
Albumin <3.3 g/dl 17.6 (75/427)
Wheelchair bound 15.8 (69/436)
6-min walk distance, m 167.5  117
5-m gait speed >6 s 84.5 (262/310)
Low grip strength* 65.7 (286/435)
Charlson comorbidity index
Mild (1–2) 8.7 (38/436)
Moderate (3–4) 32.8 (143/436)
Severe (5) 58.5 (255/436)
Quality-of-life measures
KCCQ overall summary scores 37.9  22.2
75–100 7.1 (31/436)
60–74 9.6 (42/436)
45–59 18.8 (82/436)
0–45 64.4 (281/436)
KCCQ symptoms 48.1  24.2
KCCQ physical limitation 35.3  24.9
KCCQ social limitation 30.5  28.4
KCCQ quality-of-life 36.3  24.5
SF-12 physical summary score 28.5  8.3
SF-12 mental summary score 45.8  12.3
EQ-5D 0.65  0.24
Values are mean  SD or % (n/N). *Deﬁned according to the thresholds proposed
by Luna-Heredia et al. (24).
CABG ¼ coronary artery bypass grafting; EQ-5D ¼ EuroQol-5D; KCCQ ¼ Kansas
City Cardiomyopathy Questionnaire; MI ¼myocardial infarction; NYHA¼ New York
Heart Association; SF-12 ¼ Short Form-12 General Health Survey; STS ¼ Society of
Thoracic Surgeons.
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318and 49% were male. The mean aortic valve gradient
was 48 mm Hg, and 92% were classiﬁed as New York
Heart Association functional class III to IV. The
patients had a high burden of chronic medical con-
ditions, including 30% who were on home oxygen
and 16% who were wheelchair bound. Both disease-
speciﬁc and generic health status measures demon-
strated substantial impairment at baseline. The mean
KCCQ-OS score was 37.9  22.2 (roughly comparable
to New York Heart Association functional class IV);
the mean SF-12 physical summary score was 28.5 
8.3 (w2 SD below the standard for the general U.S.
population); the mean SF-12 mental summary score
was 45.8  12.3; and the mean baseline EQ-5D score
was 0.65  0.24.
FOLLOW-UP HEALTH STATUS. Follow-up health
status data were available for 58% of surviving pa-
tients at 1 month, 74% at 6 months, and 77% at
12 months after TAVR. Mean scores and the mean
changes from baseline at each follow-up time-point
are summarized in Table 2 and Figure 2. On average,KCCQ-OS scores increased by 23.9 points at 1 month
and 27.4 points at 6 and 12 months after TAVR
compared with baseline (p < 0.001 for all compari-
sons). The individual KCCQ subscales showed similar
patterns (Table 2, Figure 2). The SF-12 physical and
TABLE 2 Mean Follow-Up Scores and Changes in Disease-Speciﬁc and
Generic Health Status Measures Compared With Baseline
Mean Value
Mean D vs.
Baseline 95% CI p Value*
KCCQ summary
1 month 62.0  25.8 23.9 20.3–27.5 <0.001
6 months 67.6  24.2 27.4 24.2–30.6 <0.001
12 months 68.5  23.6 27.4 24.1–30.8 <0.001
KCCQ total symptoms
1 month 69.0  23.8 22.1 18.6–25.7 <0.001
6 months 73.6  23.1 23.0 19.8–26.2 <0.001
12 months 74.2  21.4 22.8 19.5–26.1 <0.001
KCCQ physical limitations
1 month 53.2  30.7 16.5 12.0–21.0 <0.001
6 months 57.5  28.7 19.4 15.5–23.3 <0.001
12 months 53.7  28.6 14.1 9.9–18.2 <0.001
KCCQ social limitation
1 month 58.5  33.7 24.8 19.6–29.9 <0.001
6 months 63.8  31.2 27.2 22.4–32.1 <0.001
12 months 64.7  31.0 29.1 23.8–34.4 <0.001
KCCQ quality of life
1 month 64.7  28.1 28.9 24.7–33.0 <0.001
6 months 72.0  26.7 33.7 30.0–37.4 <0.001
12 months 74.8  25.0 36.3 32.5–40.1 <0.001
SF-12 physical
1 month 35.0  10.2 5.8 4.4–7.2 <0.001
6 months 33.6  11.3 5.0 3.5–6.4 <0.001
12 months 34.1  10.6 5.1 3.7–6.5 <0.001
SF-12 mental
1 month 49.7  12.3 3.9 1.9–5.8 <0.001
6 months 51.4  11.1 4.5 2.7–6.3 <0.001
12 months 51.7  11.8 5.1 3.3–7.0 <0.001
EQ-5D utility
1 month 0.726  0.238 0.084 0.047–0.121 <0.001
6 months 0.757  0.202 0.092 0.065–0.120 <0.001
12 months 0.727  0.208 0.058 0.027–0.090 0.003
*The p values are derived from paired t tests comparing follow-up score and baseline.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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319mental summary scores improved by w5 points at
6 and 12 months compared with baseline, and EQ-5D
utility values also increased substantially at all
time-points as well (p < 0.003 for all comparisons)
(Table 2, Figure 3).
CATEGORICAL ANALYSES. The rates of moderate
and large improvements in KCCQ-OS and favorable
and excellent outcomes at each time-point are shown
in Table 3. Among responders to the surveys, the
proportion of patients with large KCCQ-OS improve-
ments was 58% at 1 month and 59% at 12 months after
TAVR. The proportion of treated patients with an
excellent outcome (i.e., alive with a large improve-
ment in KCCQ-OS) was 52% at 1 month and 41% at 12
months after TAVR.
FACTORS ASSOCIATED WITH POOR OUTCOME.
The proportion of patients with a poor outcome was
39% at 6 months (22% death, 16% very poor quality of
life, and 1.4% quality of life decline). Pre-procedural
factors that were independently associated with a
poor outcome are shown in Table 4. Patients who
were wheelchair-bound were 2.6 times more likely to
have a poor outcome after TAVR, compared with pa-
tients who were able to ambulate (95% conﬁdence
interval: 1.3 to 5.2). In addition, having a lower aortic
valve gradient, having previous coronary artery
bypass grafting, and requiring home oxygen were
strongly associated with a poor outcome. The asso-
ciation between the Society of Thoracic Surgeons risk
score (i.e., the predicted risk of operative mortality
with surgical aortic valve replacement) and a poor
outcome of TAVR was only signiﬁcant for an STS
mortality risk >15%.
When patients were compared according to
whether they met VARC criteria for procedural suc-
cess (15), those patients who achieved procedural
success had greater improvements in health status
(mainly at the 1-month time-point) and were more
likely to experience favorable or excellent outcomes
at all time-points (Online Tables 3 and 4). After
adjusting for those pre-procedure factors summarized
in Table 4, procedural success was inversely associ-
ated with a poor outcome after TAVR (adjusted odds
ratio: 0.40, p < 0.001).
DISCUSSION
The CoreValve U.S. Extreme Risk Study has demon-
strated that TAVR using a self-expanding bio-
prosthesis is safe and effective in patients with
symptomatic severe aortic stenosis at prohibitive risk
for surgical replacement (5). In this pre-speciﬁed
quality-of-life substudy, we found that amongpatients at prohibitive risk of surgical complications,
treatment with the CoreValve device via a trans-
femoral approach leads to substantial improvement
in disease-speciﬁc and general health status. These
beneﬁts were evident by 1 month after TAVR and
were followed by modest additional improvement
through 12 months. In addition, we identiﬁed several
factors, including comorbid conditions, disability/
frailty, and valve physiology, that were indepen-
dently associated with poor outcomes after TAVR—a
ﬁnding that, if replicated in future studies, may
help to inform clinical decision-making in patients
considering TAVR.
We observed substantial improvements in both
disease-speciﬁc and generic health status measures
after TAVR. Among surviving patients, the mean
FIGURE 2 Disease-Speciﬁc Health Status After TAVR
Changes in disease-speciﬁc health status according to the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary scale (A) and
subscales (B to E) at 1, 6, and 12 months after transcatheter aortic valve replacement (TAVR). Baseline values, as indicated by the dashed line,
correspond to the evaluable patient population at each time point. Mean values and p values are derived from paired t tests comparing each
patient with his or her own baseline value.
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320improvements in the KCCQ-OS scale were >20 points
at all follow-up time-points; in previous studies, a
5-point change in this scale has been found to be
clinically meaningful and also correlates with impor-
tant differences in survival and health care costs
(16,17). Furthermore, we observed increases in SF-12physical and mental component scores of w5 points.
This increment represents twice the minimum
clinically-important difference for an individual pa-
tient (11) and is roughly comparable to reversing 10
years of normal decline in health in the general
population (18).
FIGURE 3 Generic Health Status After TAVR
Changes in generic health status according to the Short Form-12 (SF-12) (A and B) and EuroQol-5D (EQ-5D) (C) at 1, 6, and 12 months after
TAVR. Baseline values, as indicated by the dashed line, correspond to the evaluable patient population at each time point. Mean values and
p values are derived from paired t tests comparing each patient with his or her own baseline value.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 2 , 2 0 1 5 Osnabrugge et al.
F E B R U A R Y 2 0 1 5 : 3 1 5 – 2 3 Quality of Life After Self-Expanding TAVR
321Previous studies have also reported substantial
improvements in health status after surgical aortic
valve replacement (19,20) and TAVR (3,21–23).
However, most of these studies have only exam-
ined changes in generic health status. To date, only
1 other multicenter trial, the PARTNER (Placement
of AoRTic TraNscathetER Valve) trial, has rigorously
evaluated disease-speciﬁc health status after TAVR
(3,23). In PARTNER Cohort B, which included patients
who were considered surgically inoperable (i.e.,
similar to the CoreValve Extreme Risk U.S. trial),
TAVR resulted in substantial improvement in
both disease-speciﬁc and generic health status.
Although cross-trial extrapolation should be consid-
ered purely exploratory, the health status outcomes
observed in the CoreValve Extreme Risk and PARTNER
B trials were roughly comparable with respect to
both disease-speciﬁc and generic health statusmeasures through the ﬁrst year of follow-up (Online
Table 5). The current study thus conﬁrms that the
health status beneﬁts of TAVR are not restricted
solely to balloon-expandable transcatheter valves, but
also apply to the CoreValve self-expanding trans-
catheter valve.
Although many patients have excellent outcomes
after TAVR, we also found that nearly 40% of pa-
tients did not experience meaningful improvements
in survival or functional status at 6 months after
TAVR. We identiﬁed pre-operative factors that are
associated with poor outcomes, which included
measures of disability and frailty (e.g., wheelchair
dependency and low serum albumin), comorbidity
(prior coronary artery bypass grafting, extremely
high predicted surgical mortality, and oxygen de-
pendency) and valve physiology (mean aortic valve
gradient). Compared with prior work investigating
TABLE 3 Proportion of Patients With Clinically Important Improvement in
the KCCQ Summary Score
Population and Level of Beneﬁt Proportion (95% CI) [n/N]
Among responders to the survey
Moderate improvement ($10-point increase
from baseline)
1 month 70.0% (63.9–75.6) [175/250]
6 months 71.1% (65.3–76.4) [192/270]
12 months 71.3% (65.3–76.7) [181/254]
Large improvement ($20-point increase
from baseline)
1 month 58.0% (51.6–64.2) [145/250]
6 months 61.1% (55.0–67.0) [165/270]
12 months 59.1% (52.7–65.1) [150/254]
Among all treated patients*
Favorable outcome (alive with $10-point
increase from baseline)*
1 month 62.3% (56.3–68.0) [175/281]
6 months 54.9% (49.5–60.1) [192/350]
12 months 49.5% (44.2–54.7) [181/366]
Excellent outcome (alive with $20-point
increase from baseline)*
1 month 51.6% (45.6–57.6) [145/281]
6 months 47.1% (41.8–52.5) [165/350]
12 months 41.0% (35.9–46.2) [150/366]
*Denominator includes patients who died but excludes patients who voluntarily withdrew from
the study before the time point.
CI ¼ conﬁdence interval; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire.
TABLE 4 Predictors of Poor Outcome*
OR (95% CI) p Value
Baseline KCCQ overall score 1.0 (1.0–1.0) 0.488
Prior CABG 1.9 (1.2–3.3) 0.011
Mean aortic valve gradient (per 10 mm Hg)† 0.8 (0.7–0.9) 0.007
STS score‡ 0.052
10–15 1.1 (0.6–2.2)
$15 2.0 (1.1–3.7)
Home oxygen 1.7 (1.0–3.0) 0.044
Albumin <3.3 g/dl 1.8 (0.9–3.5) 0.073
Wheelchair bound 2.6 (1.3–5.2) 0.006
Model C-statistic ¼ 0.72. *Poor outcome deﬁned as: 1) death within 6 months; 2)
KCCQ overall summary score (OS) <45 points; or 3) KCCQ-OS decrease >10 points
versus baseline. †Resting gradient. ‡Reference category is STS mortality risk
score <10.
OR ¼ odds ratio; other abbreviations as in Tables 1 and 2.
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322predictors of poor outcome after TAVR in the
PARTNER population (both inoperable and high-risk
patients) we found some similar predictors (e.g.,
poor functional status, oxygen dependence, and low
aortic valve gradient) and some novel predictors
(e.g., low albumin and prior bypass surgery) in the
CoreValve population (14). Further work is needed to
establish a model that can be applied across all TAVR
patients, regardless of valve type and surgical risk,
such that patients at high risk for poor outcomes
may be identiﬁed prospectively. In the future, this
information could be invaluable to help both pa-
tients and physicians decide whether or not to un-
dergo TAVR and also to set realistic expectations for
recovery.
STUDY LIMITATIONS. First and foremost, the Cor-
eValve U.S. Extreme Risk Study was a single-arm
trial, and as such, there was no control arm to
which the results of TAVR could be compared.
Originally, the study design intended to randomize
patients to CoreValve implantation versus medical
therapy. However, after publication of the results
from Cohort B of the PARTNER trial (2), the in-
vestigators and the U.S. Food and Drug Administra-
tion felt that it was no longer ethical to randomizethese patients to standard therapy. Consequently,
we were limited to comparing health status after
TAVR with each patient’s individual baseline. Of
note, the control arm of the PARTNER B trial, which
enrolled a similar patient population, demonstrated
modest short-term improvements in health status
(most likely attributable to the high rate of balloon
aortic valvuloplasty) that were not sustained at
1 year (3). Second, the proportion of patients with
missing quality-of-life data increased modestly over
time due to both mortality and nonresponse among
surviving patients. To address this issue, we also
reported categorical outcome variables that included
all treated patients (as opposed to responding pa-
tients; i.e., excellent outcome), thereby treating pa-
tients with missing data (including death) as
“treatment failures.” If sicker patients were less
likely to respond, we may have overestimated the
extent of clinical beneﬁt. Third, our study was
restricted to the iliofemoral cohort of the CoreValve
extreme risk trial and included only 12 months of
follow-up. Thus, the durability of the observed
health status improvements, as well as the health
status improvement after noniliofemoral procedures,
remains unknown.CONCLUSIONS
In patients with severe symptomatic aortic stenosis
who are at extreme risk of surgical complications,
TAVR using the CoreValve self-expanding aortic bio-
prosthesis via a transfemoral approach resulted in
large improvements in both disease-speciﬁc and
generic health status measures in the majority of
surviving patients. Nonetheless, similar to prior
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323studies with a balloon expandable transcatheter
valve, there remains a substantial minority of pa-
tients who do not derive a meaningful survival
or quality-of-life beneﬁt from TAVR. A combination
of pre-procedural clinical, frailty, disability. and
physiological factors may provide further insight into
identifying patients who are at high risk for poor
outcomes.ACKNOWLEDGMENT The authors thank Holly Vitense
and Jane Moore for their administrative assistance.
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